Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women

• Published in: Archives of internal medicine (1960) Vol. 159; no. 13; p. 1458
• Main Authors: Col, N F, Pauker, S G, Goldberg, R J, Eckman, M H, Orr, R K, Ross, E M, Wong, J B
• Format: Journal Article
• Language: English
• Published: United States 12.07.1999
• Subjects: Alendronate - therapeutic use; Bone Density - drug effects; Breast Neoplasms - chemically induced; Coronary Disease - blood; Coronary Disease - etiology; Coronary Disease - prevention & control; Decision Support Techniques; Estrogen Replacement Therapy - adverse effects; Estrogens - agonists; Estrogens - deficiency; Estrogens, Conjugated (USP) - therapeutic use; Female; Hip Fractures - prevention & control; Humans; Life Expectancy; Lipids - blood; Markov Chains; Middle Aged; Osteoporosis, Postmenopausal - blood; Osteoporosis, Postmenopausal - etiology; Osteoporosis, Postmenopausal - prevention & control; Piperidines - therapeutic use; Postmenopause - blood; Raloxifene Hydrochloride; Risk; Risk Factors; Sensitivity and Specificity

Alendronate sodium and raloxifene hydrochloride were recently approved for the prevention of postmenopausal osteoporosis, but data on their clinical efficacy are limited. We compared these drugs with hormone replacement therapy (HRT) to help women and physicians guide postmenopausal treatment decisi...